GET DAILY SIGNALSAkebia (AKBA) Q3 2026 Results Highlight Vafseo Growth Ahead of Reimbursement Shift
Key Takeaways
- Total revenue declined to $36.9 million in the third quarter of 2026, down from $58.8 million a year earlier and below the roughly $46.9 million consensus estimate.
- Vafseo net product revenue rose 3% year over year to $14.8 million, while Auryxia revenue fell to $20.0 million under pressure from generic competition.
- The company reported a GAAP net loss of $14.4 million, or $0.05 per share, compared with net income of $0.5 million in the prior-year quarter.
- Akebia ended the quarter with $159.3 million in cash and cash equivalents, supported in part by at-the-market (ATM) equity proceeds.
- Management outlined post-TDAPA pricing of roughly $1,000 to $1,500 per patient annually as Vafseo transitions to bundled reimbursement on January 1, 2027.
Why This Quarter Matters for Akebia
Akebia Therapeutics is in the midst of a key transition for its lead product, Vafseo (vadadustat), which treats anemia linked to chronic kidney disease in dialysis patients. The third quarter of 2026 is one of the last before Vafseo’s TDAPA period ends at the start of 2027, moving the drug into the standard dialysis bundle. This update is significant because it shows whether patient growth for Vafseo can help offset the sharp drop in Auryxia sales and what the new pricing environment will look like. I’m watching closely how the latest clinical data from the VOICE and VOCAL studies balances against the softer near-term revenue picture.
Breaking Down the Reported Numbers
For the quarter ended September 30, 2026, Akebia posted total revenue of $36.9 million, a 37% drop from $58.8 million in the same quarter last year and short of the roughly $46.9 million consensus. Vafseo contributed $14.8 million, up just 3% year over year even with strong patient growth of about 140%, mainly due to an inventory adjustment from lower dosing and compliance. Auryxia revenue fell to $20.0 million from $42.5 million a year earlier because of generic competition.
The GAAP net loss came in at $14.4 million, or $0.05 per share, compared with net income of $0.5 million in the prior-year period. This was wider than the consensus loss estimate of about $0.03 per share. Cost of goods sold fell to $6.4 million, research and development expenses rose to $16.2 million, and selling, general, and administrative expenses declined to $23.5 million. A $1.3 million restructuring charge was also recorded.
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Responded
Shares of Akebia came under pressure after the report. The revenue miss and the new details on post-TDAPA pricing appeared to outweigh the positive clinical updates. The $1,000 to $1,500 annual per-patient cost range is lower than some earlier expectations, and the ongoing erosion at Auryxia added to the cautious tone even as the VOICE data showed a roughly 10% reduction in hospitalizations versus an ESA.
What to Watch Going Forward
The key date remains January 1, 2027, when Vafseo moves into the bundled reimbursement system. Management expects patient growth to continue in the fourth quarter, especially from mid-sized dialysis providers, though further inventory adjustments are likely before the change. I’m watching the rollout pace at larger organizations like DaVita and Fresenius, where the approach has been described as measured but set to accelerate in early 2027. Auryxia’s continued decline will remain a headwind, while the rare kidney disease pipeline, including Phase 2 work in FSGS and a basket trial covering C3G, IgAN, and lupus nephritis, could provide longer-term upside. With $159.3 million in cash and plans to refinance the term loan, the company expects its resources to last at least two years, making successful execution on the post-TDAPA launch the central factor for the investment case.
Exploring AI Tools for Stock Research
In my own analysis, I often turn to Tickeron’s AI Screener to quickly filter stocks and ETFs by technical patterns, fundamentals, and performance metrics. It helps surface ideas across sectors without manual effort and offers a structured way to compare opportunities like AKBA against peers, which can be useful when evaluating earnings transitions or pipeline updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AKBA's RSI Oscillator ascends from oversold territory
The RSI Oscillator for AKBA moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 34 of the 36 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AKBA as a result. In 59 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for AKBA just turned positive on October 28, 2026. Looking at past instances where AKBA's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 223 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 47 cases where AKBA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.713) is normal, around the industry mean (7.659). P/E Ratio (-3.546) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs for the treatment of anemia and vascular diseases
Industry PharmaceuticalsGeneric
Advertisement